芯导科技：2025年净利润下降4.91% 2月3日，沪市首份年报出炉，芯导科技(688230)披露的2025年年度报告，2025年实现营业收入3.94亿 元，同比增长11.52%；实现归属于上市公司股东的净利润1.06亿元，同比下降4.91%；基本每股收益为 0.9元/股。公司拟向全体股东每10股派发现金红利4.3元（含税）。 亿帆医药：维生素K1注射液获药品注册证书 2月3日，亿帆医药(002019)发布公告称，公司全资子公司合肥亿帆生物制药有限公司1月30日收到国家 药监局核准签发的维生素K1注射液《药品注册证书》。该药品用于治疗维生素K缺乏性出血和预防无法 通过营养补充的维生素K缺乏症。 勤上股份：终止回购股份减持计划 2月3日，勤上股份(002638)发布公告称，公司计划自2025年11月19日至2026年5月19日通过集中竞价交 易方式减持已回购的A股股份1649.87万股，占公司总股本的1.15%。截至目前，公司上述回购股份减持 计划尚未实施。 为稳定公司股价，增强投资者信心，公司于2026年2月2日召开董事会会议审议通过《关于终止回购股份 减持计划的议案》，决定终止上述回购股份减持计划。 极米科 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：605258 证券简称：协和电子 公告编号：2026-001 江苏协和电子股份有限公司 关于与私募基金合作投资暨参与设立股权投资基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 基本情况：江苏协和电子股份有限公司（以下简称"公司"）作为有限合伙人以自有资金500万元参与 设立常州力韧创业投资合伙企业（有限合伙）（以下简称"标的基金"或"合伙企业"），约占合伙企业认 缴出资总额的7.30%。 ● 本次交易不构成关联交易，不构成重大资产重组。 ● 审批程序：本次交易已获公司总经理办公会审批通过，无需提交董事会或股东会审议。 ● 风险提示：合伙企业设立尚需市场监督管理局等相关主管部门审核批准及备案，具体实施情况和进度 尚存在不确定性。另外，私募股权投资基金具有投资周期长、流动性低等特点，公司本次对外投资可能 面临较长的投资回收期，且投资过程可能面临宏观经济、行业周期、市场竞争、政策环境、拟投资项目 经营管理等多种因素影响，可能存在投资后无法实现 ...

格隆汇2月2日丨协和电子(605258.SH)公布，近日，为进一步落实公司投资发展规划，加强对高新技术 产业的理解与互动，开拓更丰富的产业资源，公司作为有限合伙人与常州力中投资管理有限公司、联检 （江苏）科技股份有限公司、无锡市宝森投资管理有限公司、思贝尔电力投资有限公司、黄文波、梁元 旦、周元琴、许常娥、蒋亚军及杨亚东签署《常州力韧创业投资合伙企业（有限合伙）合伙协议》 （称"《合伙协议》"），共同投资成立常州力韧创业投资合伙企业（有限合伙）。根据《合伙协议》， 合伙企业认缴出资总额为人民币6,850万元，其中公司以自有资金认缴出资500万元，约占合伙企业认缴 出资总额的7.30%。 ...

证券代码：605258 证券简称：协和电子 公告编号：2026-001 江苏协和电子股份有限公司 关于与私募基金合作投资 暨参与设立股权投资基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况：江苏协和电子股份有限公司（以下简称"公司"）作为有限合 伙人以自有资金 500 万元参与设立常州力韧创业投资合伙企业（有限合伙）（以 下简称"标的基金"或"合伙企业"），约占合伙企业认缴出资总额的 7.30%。 本次交易不构成关联交易，不构成重大资产重组。 审批程序：本次交易已获公司总经理办公会审批通过，无需提交董事会或 股东会审议。 风险提示：合伙企业设立尚需市场监督管理局等相关主管部门审核批准及 备案，具体实施情况和进度尚存在不确定性。另外，私募股权投资基金具有投资 周期长、流动性低等特点，公司本次对外投资可能面临较长的投资回收期，且投 资过程可能面临宏观经济、行业周期、市场竞争、政策环境、拟投资项目经营管 理等多种因素影响，可能存在投资后无法实现预期收益或本金损失的风险。敬请 广大投资者注意投资风险 ...

协和电子公告，公司作为有限合伙人以自有资金500万元参与设立常州力韧创业投资合伙企业（有限合 伙），约占合伙企业认缴出资总额的7.30%。合伙企业认缴出资总额为6850万元，主要投资领域为智慧 检测服务及 高端装备、 机器人及 人工智能、智慧能源等。 ...

证券代码：605258 证券简称：协和电子 公告编号：2025-043 江苏协和电子股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二）资金来源 公司部分暂时闲置的自有资金。 重要内容提示： 投资金额：拟使用单日最高余额不超过人民币 30,000 万元（含本数），在 上述额度内资金可循环投资、滚动使用，但任一时点投资余额不超过上述额度上 限。 投资种类：投资期限不超过一年的安全性高、流动性好的银行保本型理 财产品、结构性存款或低风险保本型证券公司收益凭证。 履行的审议程序：2025 年 12 月 25 日，江苏协和电子股份有限公司（以 下简称"公司"）召开第四届董事会第六次会议，审议通过了《关于使用部分闲 置自有资金进行现金管理的议案》，同意公司使用单日最高余额不超过人民币 30,000 万元的闲置自有资金进行现金管理，在上述额度内资金可循环投资、滚动 使用，但任一时点投资余额不超过上述额度上限。本次事项无需提交股东大会审 议。 特别风险提示：尽管公司购买的理财产品为 ...

Core Viewpoint - The company, Xiehe Electronics (605258.SH), plans to utilize a maximum balance of RMB 300 million of temporarily idle self-owned funds for cash management, effective for 12 months from the date of approval by the fourth board of directors' sixth meeting [1] Group 1 - The maximum amount for cash management is set at RMB 300 million [1] - The cash management period is valid for 12 months from the board's approval [1] - The approved amount can be used on a rolling basis within the specified period [1]

Key Points - The article discusses significant fund establishment events in China from December 15 to December 21, highlighting various government and private sector initiatives aimed at fostering innovation and investment in key industries [5]. Government-Backed Funds - Shenzhen has established a new fund, the Shenzhen National Innovation Fund, with a total capital of 18.9 billion RMB, focusing on venture capital investments in unlisted companies [7]. - Inner Mongolia has launched a 6 billion RMB mother fund for strategic emerging industries, with a focus on attracting social capital for investments in nine key sectors, including new information technology and high-end equipment manufacturing [8]. - Jinan has initiated a 5 billion RMB artificial intelligence industry fund to support hard technology sectors, including model development and intelligent computing [9]. - Beijing's Fengtai District has set up a 5 billion RMB government investment mother fund to enhance regional industrial ecosystems [9]. - Chaoyang District in Beijing has created two 20 billion RMB funds to support digital economy development, focusing on various emerging industries [10]. Private Sector Initiatives - The Xuzhou Guorun Industry Investment Fund has been established with a total scale of 2 billion RMB, targeting strategic emerging industries and future industries [10]. - Hubei Cultural Tourism Group and Jingmen City have signed an agreement to establish a 1 billion RMB aerospace and digital industry fund, focusing on low-altitude economy sectors [11]. - The Hangzhou Western Common Prosperity Fund has been launched with a total scale of 1 billion RMB, aimed at supporting high-quality projects in the region [12]. - The Suqian New Materials Mother Fund has successfully registered its first sub-fund with a scale of 500 million RMB, focusing on key material sectors [12]. Academic and Collaborative Funds - Wuhan University of Science and Technology has initiated a 200 million RMB seed fund in collaboration with local government and industry partners, focusing on early-stage technology projects [13]. - Tianjin Economic Development Zone has established a 120 million RMB new venture capital fund, targeting hard technology sectors [14]. - The Nanjing AIC Fund has completed its first project investment of 50 million RMB in a key industrial digital transformation company [15]. Emerging Industry Focus - The Yunnan Advanced Manufacturing Equity Investment Mother Fund has been registered, focusing on traditional industry upgrades and strategic emerging industries [16][17]. - The Hubei Port and Shipping Development Fund is seeking to recruit fund management institutions to invest in logistics and transportation sectors [18]. - The Hainan Aerospace Star Arrow Manufacturing Fund aims to attract social capital for aerospace-related investments, with a target scale of 3 billion RMB [19]. Conclusion - The article emphasizes the growing trend of establishing various funds across China, driven by both government and private sectors, to support innovation and development in key industries, particularly in technology and manufacturing sectors [5].

Core Viewpoint - Jiangsu Xiehe Electronics Co., Ltd. has invested 5 million yuan as a limited partner in the Wuxi Xingqi Yuzheng Venture Capital Partnership, acquiring approximately 2.2936% of the partnership shares, which totals 218 million yuan [2][3][28] Group 1: Investment Details - The company has subscribed to the partnership shares using its own funds, amounting to 5 million yuan [2][3] - The total capital commitment of the target fund, Wuxi Xingqi Yuzheng, is 218 million yuan [2][3] - The investment does not constitute a related party transaction or a major asset restructuring [2][4] Group 2: Approval Process - The transaction was approved within the authority of the company's general manager's office and does not require board or shareholder approval [2][4] Group 3: Purpose and Scope of Partnership - The partnership aims to protect the rights of all partners and generate returns through equity investment management [7] - The fund will primarily invest in high-tech sectors such as automotive, semiconductors, and intelligent manufacturing [21] Group 4: Financial Impact - The investment is made while ensuring the company's main business remains stable, aiming to enhance understanding and interaction with high-tech industries [28] - The investment will not significantly impact the company's financial and operational status, aligning with the overall development needs of the company [28]

Group 1 - Sichuan Chengyu's wholly-owned subsidiary plans to acquire 85% equity of Hubei Jingyi Company for 2.409 billion yuan, enhancing the company's control over highway projects [1] - Huadian Technology signed contracts worth approximately 815 million yuan with Huadian Technology Group for a wind power hydrogen production project [2] - Dongfang Cable and its subsidiary won projects totaling approximately 3.125 billion yuan, accounting for 34.37% of the company's audited revenue for 2024 [3] Group 2 - Heng Rui Medicine received approval for clinical trials of SHR-2906 injection, a self-developed biopharmaceutical aimed at weight control and metabolic regulation [4] - Qingdao Port plans to invest approximately 15.7 billion yuan in two terminal projects [5] - Jingu Co. received a notification to supply low-carbon wheels for two export models to a major domestic car manufacturer, with production expected in 2026 [6] Group 3 - ST Xingguang won a procurement project worth approximately 22.955 million yuan, accounting for 11.96% of the company's revenue for 2024 [7] - Xinbo Co. plans to jointly invest in an alloy materials research institute with partners, focusing on high-performance materials for various industries [8] - Tianqi Lithium's third-phase lithium concentrate expansion project has been completed and is undergoing trial production, with a total capacity of 2.14 million tons per year [9] Group 4 - Changfei Fiber reported that new fiber optic products related to data centers represent a small proportion of total demand [10] - Dongfang Bio's subsidiaries obtained multiple medical device registration certificates, including various testing kits [11] - Xiugang Co. plans to use up to 500 million yuan of idle fundraising for cash management in safe, liquid investment products [12] Group 5 - Jifeng Co. received a project designation for passenger car seat assemblies from a European luxury brand, with a total lifecycle value of approximately 9.8 billion yuan [13] - CanSino initiated Phase I clinical trials for a combined vaccine, completing the first subject enrollment [14] - Dayu Water-saving's subsidiary pre-won a drainage project worth 140 million yuan and another project worth 1 billion yuan [15] Group 6 - Yutong Pharmaceutical's subsidiary received clinical trial approval for YKYY032 injection for treating hyperlipoproteinemia [17] - Diweier announced the departure of a core technical personnel, impacting its technical leadership [18] - Weilang Co.'s controlling shareholder received regulatory measures from the Shandong Securities Regulatory Bureau for failing to fulfill a commitment [19] Group 7 - Xiehe Electronics invested 5 million yuan in a private equity fund focusing on hard technology sectors [20] - Phoenix Optical received a government subsidy of 4.7053 million yuan, representing 35% of its projected net profit for 2024 [21] - China State Construction reported a 0.9% year-on-year increase in new contracts signed in the first 11 months of 2025, totaling 4.0408 trillion yuan [22] Group 8 - Nanguang Energy's pumped storage power station units 1 and 2 have entered trial operation, with units 3 and 4 expected to follow by year-end [23] - Jindalai plans to invest 280 million yuan to acquire a 34% stake in Yunnan Jici Medical Technology [24] - Geer Software terminated its planned acquisition of a majority stake in Weipin Zhiyuan due to failure to reach agreement on key terms [25] Group 9 - Ningbo Fubang completed the absorption merger of its wholly-owned subsidiary, inheriting all assets and liabilities [26] - Zhongyuan Neipei signed a strategic cooperation framework agreement with Ningbo Puzhi Company for humanoid robot-related business [28] - Gongyuan Co. announced a business integration and relocation of its production lines in the East China region [29] Group 10 - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in a comprehensive utilization project for waste salt [30] - Kain Technology announced the departure of a core technical personnel, impacting its research capabilities [31] - ST Renfu received approval for clinical trials of a new drug for idiopathic pulmonary fibrosis [32] Group 11 - Sanbo Brain Science's established brain science fund has completed registration with the Asset Management Association of China [33] - Tongyou Technology plans to apply for a 70 million yuan credit line from Beijing Bank, using its property as collateral [34] - Bai Ao Intelligent signed a significant equipment sales contract worth approximately 27.5021 million yuan [35] Group 12 - ST Xinyan received all restructuring investment funds totaling 2.239 billion yuan, entering the execution phase of its restructuring plan [36] - Dalu Real Estate's subsidiary decided to terminate a planned acquisition of a 60% stake in Beijing Chengzhu Real Estate [38] - Huiyu Pharmaceutical's products received marketing approval in Italy and Norway [39]